AbbVie annual operating cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Operating Cash Flow Growth & History (ABBV)
AbbVie's operating cash flow was $19.03B for fiscal 2025.
View full AbbVie company overviewAbbVie annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.03B | $224.0M | +1.19% |
| 2024 | 2024-12-31 | $18.81B | −$4.03B | −17.66% |
| 2023 | 2023-12-31 | $22.84B | −$2.10B | −8.44% |
| 2022 | 2022-12-31 | $24.94B | $2.17B | +9.51% |
| 2021 | 2021-12-31 | $22.78B | $5.19B | +29.50% |
| 2020 | 2020-12-31 | $17.59B | $4.26B | +32.00% |
| 2019 | 2019-12-31 | $13.32B | −$103.0M | −0.77% |
| 2018 | 2018-12-31 | $13.43B | $3.47B | +34.81% |
| 2017 | 2017-12-31 | $9.96B | $2.92B | +41.46% |
| 2016 | 2016-12-31 | $7.04B | −$494.0M | −6.56% |
| 2015 | 2015-12-31 | $7.54B | $3.99B | +112.31% |
| 2014 | 2014-12-31 | $3.55B | −$2.72B | −43.37% |
| 2013 | 2013-12-31 | $6.27B | −$78.0M | −1.23% |
| 2012 | 2012-12-31 | $6.34B | $98.0M | +1.57% |
| 2011 | 2011-12-31 | $6.25B | — | — |
AbbVie quarterly operating cash flow
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.44B | −$1.72B | −33.32% |
| Q1 2026 | 2026-03-31 | $3.83B | $2.19B | +134.19% |
| Q4 2025 | 2025-12-31 | $5.22B | −$1.83B | −25.96% |
| Q3 2025 | 2025-09-30 | $7.02B | $1.58B | +28.95% |
| Q2 2025 | 2025-06-30 | $5.15B | $2.88B | +126.90% |
| Q1 2025 | 2025-03-31 | $1.64B | −$2.40B | −59.53% |
| Q4 2024 | 2024-12-31 | $7.05B | — | — |
| Q3 2024 | 2024-09-30 | $5.45B | −$2.13B | −28.08% |
| Q2 2024 | 2024-06-30 | $2.27B | −$4.05B | −64.06% |
| Q1 2024 | 2024-03-31 | $4.04B | −$153.0M | −3.65% |
| Q3 2023 · Sep 30 | 2023-09-30 | $7.57B | −$28.0M | −0.37% |
| Q2 2023 · Jun 30 | 2023-06-30 | $6.32B | $1.31B | +26.25% |
| Q1 2023 · Mar 31 | 2023-03-31 | $4.19B | −$715.0M | −14.57% |
| Q3 2022 · Sep 30 | 2022-09-30 | $7.60B | −$333.0M | −4.20% |
| Q2 2022 · Jun 30 | 2022-06-30 | $5.00B | $115.0M | +2.35% |
| Q1 2022 · Mar 31 | 2022-03-31 | $4.91B | $31.0M | +0.64% |
| Q3 2021 · Sep 30 | 2021-09-30 | $7.93B | $2.10B | +36.11% |
| Q2 2021 · Jun 30 | 2021-06-30 | $4.89B | $1.80B | +58.30% |
| Q1 2021 · Mar 31 | 2021-03-31 | $4.88B | $1.06B | +27.84% |
| Q3 2020 · Sep 30 | 2020-09-30 | $5.83B | $1.27B | +27.99% |
| Q2 2020 · Jun 30 | 2020-06-30 | $3.09B | $612.0M | +24.71% |
| Q1 2020 · Mar 31 | 2020-03-31 | $3.81B | $798.0M | +26.45% |
| Q3 2019 · Sep 30 | 2019-09-30 | $4.55B | $31.0M | +0.69% |
| Q2 2019 · Jun 30 | 2019-06-30 | $2.48B | −$389.0M | −13.57% |
| Q1 2019 · Mar 31 | 2019-03-31 | $3.02B | $372.0M | +14.06% |
| Q3 2018 · Sep 30 | 2018-09-30 | $4.52B | $1.25B | +38.31% |
| Q2 2018 · Jun 30 | 2018-06-30 | $2.87B | $863.0M | +43.09% |
| Q1 2018 · Mar 31 | 2018-03-31 | $2.65B | $543.0M | +25.83% |
| Q3 2017 · Sep 30 | 2017-09-30 | $3.27B | $1.82B | +124.97% |
| Q2 2017 · Jun 30 | 2017-06-30 | $2.00B | $85.0M | +4.43% |
| Q1 2017 · Mar 31 | 2017-03-31 | $2.10B | −$26.0M | −1.22% |
| Q3 2016 · Sep 30 | 2016-09-30 | $1.45B | −$701.0M | −32.53% |
| Q2 2016 · Jun 30 | 2016-06-30 | $1.92B | $86.0M | +4.69% |
| Q1 2016 · Mar 31 | 2016-03-31 | $2.13B | $543.0M | +34.26% |
| Q3 2015 · Sep 30 | 2015-09-30 | $2.15B | $369.0M | +20.66% |
| Q2 2015 · Jun 30 | 2015-06-30 | $1.83B | $115.0M | +6.70% |
| Q1 2015 · Mar 31 | 2015-03-31 | $1.58B | $961.0M | +154.01% |
| Q4 2014 | 2014-12-31 | −$578.0M | −$1.82B | — |
| Q3 2014 | 2014-09-30 | $1.79B | −$12.0M | −0.67% |
| Q2 2014 | 2014-06-30 | $1.72B | −$320.0M | −15.71% |
| Q1 2014 | 2014-03-31 | $624.0M | −$563.0M | −47.43% |
| Q4 2013 | 2013-12-31 | $1.25B | $304.0M | +32.31% |
| Q3 2013 | 2013-09-30 | $1.80B | −$451.0M | −20.05% |
| Q2 2013 | 2013-06-30 | $2.04B | $476.0M | +30.49% |
| Q1 2013 | 2013-03-31 | $1.19B | −$407.0M | −25.53% |
| Q4 2012 | 2012-12-31 | $941.0M | — | — |
| Q3 2012 | 2012-09-30 | $2.25B | — | — |
| Q2 2012 | 2012-06-30 | $1.56B | — | — |
| Q1 2012 | 2012-03-31 | $1.59B | — | — |
AbbVie operating cash flow trends
Over the last five fiscal years, AbbVie's operating cash flow increased from $17.59B to $19.03B, a change of $1.44B. The latest reported quarter, Q2 2026, shows $3.44B.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...